Dr Reddy's launches Bicalutamide drug for prostate cancer for the first time in India
Thursday, March 28, 2002 08:00 IST Our Bureau, Hyderabad
Dr Reddy's Laboratories Ltd launched Tabi (Bicalutamide ) which is indicated for the treatment of advanced prostate cancer. Dr Reddy's is the first company to launch this once daily drug in India.
The company will market the product under the brand name Tabi. The product will be available as a 50mg tablet, with a global market share of over 50%, Bicalutamide is the world's leading anti-androgen therapy for the treatment of advanced prostate cancer.
Bicalutamide, with its once-a-day dosage, is expected to provide higher patient compliance and preference. In comparison, Flutamide, the currently available anti-androgen drug, has thrice a day dosage.